Can Mid-Cap Lantheus Continue its 2022 Outperformance? - Rickey J. White, Jr. | RJW™
28599
post-template-default,single,single-post,postid-28599,single-format-standard,bridge-core-3.3.2,qode-optimizer-1.0.3,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-30.8.3,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-8.0,vc_responsive
 

Can Mid-Cap Lantheus Continue its 2022 Outperformance?

28 Oct Can Mid-Cap Lantheus Continue its 2022 Outperformance?

Posted at 07:00h in Popular Newsfeed by
0 Likes

Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.
Source: Entrepreneur.com Lastest News

Tags:
No Comments

Sorry, the comment form is closed at this time.